187 related articles for article (PubMed ID: 11215878)
21. [Severe tardive dyskinesia during treatment with risperidone and fluoxetine].
Dubbelman YD; Thung FH; Heeringa M
Ned Tijdschr Geneeskd; 1998 Jun; 142(26):1508-11. PubMed ID: 9752071
[TBL] [Abstract][Full Text] [Related]
22. Life-threatening tardive dyskinesia.
Chiu HF; Chung DW; Wing YK; Wong CK
Br J Clin Pract; 1996; 50(3):175-6. PubMed ID: 8733342
[TBL] [Abstract][Full Text] [Related]
23. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Tune LE
J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
[TBL] [Abstract][Full Text] [Related]
24. Risperidone and tardive dyskinesia: a case of blepharospasm.
Mullen A
Aust N Z J Psychiatry; 2000 Oct; 34(5):879-80. PubMed ID: 11037386
[No Abstract] [Full Text] [Related]
25. Acute and long-term treatment of catatonia with risperidone.
Hesslinger B; Walden J; Normann C
Pharmacopsychiatry; 2001 Jan; 34(1):25-6. PubMed ID: 11229618
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
27. Treatment of a tardive dyskinesia patient with temporomandibular disorder: a case report.
Pekkan G; Kilicoglu A; Algin DI
J Orofac Pain; 2010; 24(2):212-6. PubMed ID: 20401360
[TBL] [Abstract][Full Text] [Related]
28. The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.
Peritogiannis V; Tsouli S
J Clin Psychiatry; 2011 Jul; 72(7):1016; author reply 1016-7. PubMed ID: 21824463
[No Abstract] [Full Text] [Related]
29. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
[TBL] [Abstract][Full Text] [Related]
30. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
31. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
[TBL] [Abstract][Full Text] [Related]
32. Clozapine efficacy in tardive dyskinesia in schizophrenic patients.
Bassitt DP; Louzã Neto MR
Eur Arch Psychiatry Clin Neurosci; 1998; 248(4):209-11. PubMed ID: 9810484
[TBL] [Abstract][Full Text] [Related]
33. Risperidone treatment of tardive dyskinesia and dystonia.
Chong SA; Remington G; Tan CH
J Clin Psychiatry; 1999 May; 60(5):340-1. PubMed ID: 10362448
[No Abstract] [Full Text] [Related]
34. [The intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].
Brunner E; Gargoloff P; Caro O; González C; Landa E; González CH; Barahona A; Soria D; Tamayo J; Rovner J; Adrianzen C; Silva H; Hodge A; O'Halloran R; Assunção SS;
Actas Esp Psiquiatr; 2006; 34(1):16-27. PubMed ID: 16525901
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
36. Direct transition to long-acting risperidone--analysis of long-term efficacy.
Kissling W; Heres S; Lloyd K; Sacchetti E; Bouhours P; Medori R; Llorca PM
J Psychopharmacol; 2005 Sep; 19(5 Suppl):15-21. PubMed ID: 16144782
[TBL] [Abstract][Full Text] [Related]
37. Risperidone and tardive dyskinesia in organic psychosis.
Fischer P; Tauscher J; Küfferle B
Pharmacopsychiatry; 1998 Mar; 31(2):70-1. PubMed ID: 9562212
[No Abstract] [Full Text] [Related]
38. Levetiracetam in tardive dyskinesia.
Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
[TBL] [Abstract][Full Text] [Related]
39. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.
Kane JM
J Clin Psychiatry; 2004; 65 Suppl 9():16-20. PubMed ID: 15189107
[TBL] [Abstract][Full Text] [Related]
40. Risperidone for tardive dyskinesia.
Chen JY; Bai YM; Pyng LY; Lin CC
Am J Psychiatry; 2001 Nov; 158(11):1931-2. PubMed ID: 11691710
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
